Access Program Information
Primary Objectives:
– Provide palliative therapy with 131I-MIBG for patients with advanced neuroblastoma,
pheochromocytoma, or paraganglioma.
– Gain more information about acute and late toxicity of 131I-MIBG therapy for patients
with refractory neuroblastoma, pheochromocytoma, or paraganglioma.